We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Ortho Tri-Clyclen Tablets (norgestimate/ethinyl estradiol) has been approved as a treatment for acne in women seeking contraception.

    Varying levels of severity of acne at different points of the menstrual cycle have been reported. Research has demonstrated that Ortho Tri-Cyclen decreases the level of hormones, which contribute to the development of acne-producing agents, thus attacking the cause of the acne.

    Ortho Tri-Cyclen, introduced in 1992, is the only oral contraceptive cleared in the United States for the treatment of moderate acne vulgaris in women 15 years of age or older; who have no known contraindication to oral contraceptive therapy; who desire contraception; who have begun menstruation and who are unresponsive to topical anti-acne medications. It is also indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

    Clinical Results

    In the clinical studies, Ortho Tri-Cyclen showed improvement of acne similar to those seen in studies looking at efficacy or benzoyl peroxide and topical or systemic antibiotics. Ortho Tri-Cyclen treats acne with a combination of ethinyl estradiol, a synthetic estrogen, and norgestimate, a progestin. Two randomized, double-blind, placebo-controlled studies demonstrated that improvement of acne was reported during use of Ortho Tri-Cyclen in more than 80 percent of the studies’ participants treated with Ortho Tri-Cyclen.

    Approval Date: 1997-01-01
    Date Created: 1997-01-13 12:00:00
    Company Name: Ortho-McNeil Pharmaceutical
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing